Publications by authors named "Mohammadreza Sheikhy-Chaman"
Purpose: Cancer is the second leading cause of mortality in Iran, significantly impacting patients' lives and the public health system. This study aims to investigate changes in employment status and income and workplace organizational support among Iranian cancer survivors following their diagnosis.
Methods: This study was conducted at the Cancer Institute of Imam Khomeini Hospital complex in Tehran, Iran, in 2019.
Article Synopsis
- This study investigates how the COVID-19 pandemic impacted households in Iran regarding catastrophic health expenditures (CHE), which occur when out-of-pocket health payments exceed 40% of a household’s spending capacity.
- Data was collected from two national income and expenditure surveys in 2020 and 2021 to assess changes in average out-of-pocket payments and the prevalence of CHE in both urban and rural areas.
- Findings show that average OOP health payments rose in 2021, with urban households consistently paying more than rural ones; the national prevalence of CHE increased from 2.92% in 2020 to 3.18% in 2021, indicating a growing financial strain related to health costs.
In recent years, massively parallel sequencing or next generation sequencing (NGS) has considerably changed both the research and diagnostic fields, and rapid developments have led to the combination of NGS techniques in clinical practice, ease of analysis, and detection of genetic mutations. This article aimed at reviewing the economic evaluation studies of the NGS techniques in the diagnosis of genetic diseases. In this systematic review, scientific databases (PubMed, EMBASE, Web of Science, Cochrane, Scopus, and CEA registry) were searched from 2005 to 2022 to identify the related literature on the economic evaluation of NGS techniques in the diagnosis of genetic diseases.
View Article and Find Full Text PDFIntroduction: Dapagliflozin, a new treatment option for heart failure, leads to a significant reduction in the hospitalization of patients with heart failure. We aimed to review studies on the economic evaluation of adding dapagliflozin to standard care compared with standard care alone in heart failure patients with reduced ejection fraction (HFrEF).
Methods: For this systematic review, the PubMed, EMBASE, Web of Science, Cochrane, Scopus, and CEA Registry scientific databases were searched from 1 January 2020 to 25 March 2022.